Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society
Abstract
Down syndrome (DS), or trisomy 21 (T21), represents the most common genetic cause of intellectual disability worldwide and is associated with a wide range of medical, developmental, and neurodegenerative conditions, including a universal predisposition to early-onset Alzheimer's disease (AD). Since its establishment in 2014, the Trisomy 21 Research Society (T21RS) has provided a global forum for advancing DS research across disciplines and promoting translational efforts to improve health and quality of life. Every two years, T21RS hosts an international scientific meeting that brings together researchers, clinicians, self-advocates, families, and industry stakeholders. In 2024, the 5th T21RS International Conference was held in Rome, Italy, from June 5 to 8, under the theme "Promoting Research Excellence in Down Syndrome." The meeting brought together about 500 scientists from 26 countries across five continents, and more than 900 attendees overall, including families and caregivers. The scientific program featured 5 keynote lectures, 2 satellite meetings, 17 symposia, 7 nano symposia, 2 workshops, and 1 industry-focused session, totaling more than 150 oral presentations. More than 230 abstracts were presented as posters. The conference covered research across the lifespan of individuals with DS, spanning genomic and epigenetic regulation, molecular and cellular mechanisms, preclinical and experimental models, cognition and behavior, neurodevelopment, aging and neurodegeneration, co-occurring medical conditions, and therapeutic interventions. Dedicated sessions focused on capacity-building in DS research and societal engagement were established. Significantly, T21RS promoted inclusivity by supporting 60 young investigator fellowships, providing childcare awards, and organizing a two-day program for families and caregivers in collaboration with Italian DS associations. This proceeding summarizes the main scientific highlights of the 5th T21RS International Conference, reflecting the latest advances in DS biology, clinical research, biomarker development, and therapeutic innovation.
Related
- A 35-Year-Old Woman With Multiple Sclerosis and a New Atypical Thalamic Lesion: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings.
- Abstracts from the 15th International Conference for Healthcare and Medical Students (ICHAMS).
- Exposure and impact: highlights from the second scientific conference and recent activities of the International Society of Radiation Epidemiology and Dosimetry (ISoRED)
- Consensus Statement on Traumatic Brain Injury in First Responders: The 1st International Conference on TBI in First Responders
- A novel, free regional conference model to increase interest and engagement of medical trainees in pediatrics and pediatric gastroenterology research
BibTeX
@article{domenico2026promoting,
title = {{Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society}},
author = {Fabio Di Domenico and Marzia Perluigi and Antonella Tramutola and Maria Giulia Bacalini and Daniella Balduino Victorino and Isabel Barroeta and Renata Bartesaghi and Angelo Carfi and Maria Carmona-Iragui and Ann Cohen and Alberto Costa and Floriana Costanzo and Mara Dierssen and Lauren Dunn and Marco Emili and Edward Evans and Clíona Farrell and Lisi Flores-Aguilar and Abi Fukami-Gartner and Sandra Gimenez and Ann-Charlotte Granholm and Thessa Hilgenkamp and Antonella Izzo and Sharon Krinsky-Mchale and Laura del Hoyo Soriano and Laurent Meijer and Bill Mobley and Ivan Moskowitz and Dean Nizetic and Jonathan Pierce and Lauren Ptomey and Angela Rachubinski and Anne-Sophie Rebillat and Randall Roper and Jonathan Santoro and Brian Skotko and Fiorenza Stagni and Andre Strydom and Louis Valay and Shahid Zaman and Bruna Lancia Zampieri and Jonathan Pierce and Thessa Hilgenkamp and Fiorenza Stagni and Marco Emili and Frances Wiseman and Randall Ropper and María Carmona-Iragui and Anne-Sophie Rebillat and Eugenio Barone and Marzia Perluigi and Brian Skotko and Shahid Zaman and Esteban Rozen and Ann-Charlotte Granholm-Bentley and Renata Bartesaghi and William Mobley and Jean-Maurice Delabar and Mara Dierssen and Roger Reeves},
journal = {NeuroMolecular Medicine},
year = {2026},
month = jun,
doi = {10.1007/s12017-026-08921-0},
url = {https://hal.science/hal-05844256v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society
AU - Fabio Di Domenico
AU - Marzia Perluigi
AU - Antonella Tramutola
AU - Maria Giulia Bacalini
AU - Daniella Balduino Victorino
AU - Isabel Barroeta
AU - Renata Bartesaghi
AU - Angelo Carfi
AU - Maria Carmona-Iragui
AU - Ann Cohen
AU - Alberto Costa
AU - Floriana Costanzo
AU - Mara Dierssen
AU - Lauren Dunn
AU - Marco Emili
AU - Edward Evans
AU - Clíona Farrell
AU - Lisi Flores-Aguilar
AU - Abi Fukami-Gartner
AU - Sandra Gimenez
AU - Ann-Charlotte Granholm
AU - Thessa Hilgenkamp
AU - Antonella Izzo
AU - Sharon Krinsky-Mchale
AU - Laura del Hoyo Soriano
AU - Laurent Meijer
AU - Bill Mobley
AU - Ivan Moskowitz
AU - Dean Nizetic
AU - Jonathan Pierce
AU - Lauren Ptomey
AU - Angela Rachubinski
AU - Anne-Sophie Rebillat
AU - Randall Roper
AU - Jonathan Santoro
AU - Brian Skotko
AU - Fiorenza Stagni
AU - Andre Strydom
AU - Louis Valay
AU - Shahid Zaman
AU - Bruna Lancia Zampieri
AU - Jonathan Pierce
AU - Thessa Hilgenkamp
AU - Fiorenza Stagni
AU - Marco Emili
AU - Frances Wiseman
AU - Randall Ropper
AU - María Carmona-Iragui
AU - Anne-Sophie Rebillat
AU - Eugenio Barone
AU - Marzia Perluigi
AU - Brian Skotko
AU - Shahid Zaman
AU - Esteban Rozen
AU - Ann-Charlotte Granholm-Bentley
AU - Renata Bartesaghi
AU - William Mobley
AU - Jean-Maurice Delabar
AU - Mara Dierssen
AU - Roger Reeves
PY - 2026
DA - 2026/06/06
JO - NeuroMolecular Medicine
DO - 10.1007/s12017-026-08921-0
UR - https://hal.science/hal-05844256v1
AB - Down syndrome (DS), or trisomy 21 (T21), represents the most common genetic cause of intellectual disability worldwide and is associated with a wide range of medical, developmental, and neurodegenerative conditions, including a universal predisposition to early-onset Alzheimer's disease (AD). Since its establishment in 2014, the Trisomy 21 Research Society (T21RS) has provided a global forum for advancing DS research across disciplines and promoting translational efforts to improve health and quality of life. Every two years, T21RS hosts an international scientific meeting that brings together researchers, clinicians, self-advocates, families, and industry stakeholders. In 2024, the 5th T21RS International Conference was held in Rome, Italy, from June 5 to 8, under the theme "Promoting Research Excellence in Down Syndrome." The meeting brought together about 500 scientists from 26 countries across five continents, and more than 900 attendees overall, including families and caregivers. The scientific program featured 5 keynote lectures, 2 satellite meetings, 17 symposia, 7 nano symposia, 2 workshops, and 1 industry-focused session, totaling more than 150 oral presentations. More than 230 abstracts were presented as posters. The conference covered research across the lifespan of individuals with DS, spanning genomic and epigenetic regulation, molecular and cellular mechanisms, preclinical and experimental models, cognition and behavior, neurodevelopment, aging and neurodegeneration, co-occurring medical conditions, and therapeutic interventions. Dedicated sessions focused on capacity-building in DS research and societal engagement were established. Significantly, T21RS promoted inclusivity by supporting 60 young investigator fellowships, providing childcare awards, and organizing a two-day program for families and caregivers in collaboration with Italian DS associations. This proceeding summarizes the main scientific highlights of the 5th T21RS International Conference, reflecting the latest advances in DS biology, clinical research, biomarker development, and therapeutic innovation.
SN - 1535-1084
ER -